vs
MERIT MEDICAL SYSTEMS INC（MMSI）与Orchestra BioMed Holdings, Inc.（OBIO）财务数据对比。点击上方公司名可切换其他公司
MERIT MEDICAL SYSTEMS INC的季度营收约是Orchestra BioMed Holdings, Inc.的12.7倍（$393.9M vs $30.9M）。Orchestra BioMed Holdings, Inc.净利率更高（20.2% vs 9.6%，领先10.6%）。Orchestra BioMed Holdings, Inc.同比增速更快（12120.2% vs 10.9%）。MERIT MEDICAL SYSTEMS INC自由现金流更多（$74.0M vs $-2.3M）。过去两年Orchestra BioMed Holdings, Inc.的营收复合增速更高（606.2% vs 10.3%）
梅里特医疗系统公司是一家全球性医疗设备企业，设计、生产和销售适用于心脏病学、放射学、肿瘤学、内窥镜及重症监护领域的介入和诊断产品，为全球医院及医疗机构提供微创医疗解决方案，助力提升患者疗效和临床操作效率。
Orchestra BioMed Holdings是一家临床阶段医疗科技企业，专注于开发针对心血管及其他高负担慢性疾病的新型循证治疗方案，核心业务覆盖介入心脏病学、慢病护理优化等领域，主要面向北美、欧洲市场运营，与头部医疗行业参与者开展合作。
MMSI vs OBIO — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $393.9M | $30.9M |
| 净利润 | $38.0M | $6.2M |
| 毛利率 | 49.6% | 99.8% |
| 营业利润率 | 13.8% | 21.8% |
| 净利率 | 9.6% | 20.2% |
| 营收同比 | 10.9% | 12120.2% |
| 净利润同比 | 36.0% | 138.7% |
| 每股收益（稀释后） | $0.64 | $0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $393.9M | $30.9M | ||
| Q3 25 | $384.2M | $861.0K | ||
| Q2 25 | $382.5M | $836.0K | ||
| Q1 25 | $355.4M | $868.0K | ||
| Q4 24 | $355.2M | $253.0K | ||
| Q3 24 | $339.8M | $987.0K | ||
| Q2 24 | $338.0M | $778.0K | ||
| Q1 24 | $323.5M | $620.0K |
| Q4 25 | $38.0M | $6.2M | ||
| Q3 25 | $27.8M | $-20.8M | ||
| Q2 25 | $32.6M | $-19.4M | ||
| Q1 25 | $30.1M | $-18.8M | ||
| Q4 24 | $27.9M | $-16.2M | ||
| Q3 24 | $28.4M | $-15.4M | ||
| Q2 24 | $35.7M | $-16.0M | ||
| Q1 24 | $28.2M | $-13.5M |
| Q4 25 | 49.6% | 99.8% | ||
| Q3 25 | 48.5% | 94.3% | ||
| Q2 25 | 48.2% | 94.5% | ||
| Q1 25 | 48.4% | 94.9% | ||
| Q4 24 | 48.7% | 77.1% | ||
| Q3 24 | 46.4% | 93.1% | ||
| Q2 24 | 47.7% | 94.3% | ||
| Q1 24 | 46.9% | 94.5% |
| Q4 25 | 13.8% | 21.8% | ||
| Q3 25 | 11.1% | -2359.2% | ||
| Q2 25 | 12.3% | -2311.8% | ||
| Q1 25 | 11.5% | -2179.8% | ||
| Q4 24 | 10.3% | -6591.7% | ||
| Q3 24 | 11.0% | -1655.7% | ||
| Q2 24 | 13.6% | -2167.0% | ||
| Q1 24 | 11.1% | -2326.3% |
| Q4 25 | 9.6% | 20.2% | ||
| Q3 25 | 7.2% | -2419.0% | ||
| Q2 25 | 8.5% | -2316.1% | ||
| Q1 25 | 8.5% | -2160.7% | ||
| Q4 24 | 7.9% | -6385.4% | ||
| Q3 24 | 8.4% | -1562.9% | ||
| Q2 24 | 10.6% | -2054.0% | ||
| Q1 24 | 8.7% | -2171.5% |
| Q4 25 | $0.64 | $0.28 | ||
| Q3 25 | $0.46 | $-0.40 | ||
| Q2 25 | $0.54 | $-0.50 | ||
| Q1 25 | $0.49 | $-0.49 | ||
| Q4 24 | $0.46 | $-0.42 | ||
| Q3 24 | $0.48 | $-0.41 | ||
| Q2 24 | $0.61 | $-0.45 | ||
| Q1 24 | $0.48 | $-0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $446.4M | $106.5M |
| 总债务越低越好 | $734.0M | $15.0M |
| 股东权益账面价值 | $1.6B | $53.6M |
| 总资产 | $2.7B | $114.9M |
| 负债/权益比越低杠杆越低 | 0.46× | 0.28× |
8季度趋势，按日历期对齐
| Q4 25 | $446.4M | $106.5M | ||
| Q3 25 | $392.5M | $95.8M | ||
| Q2 25 | $341.8M | $33.9M | ||
| Q1 25 | $395.5M | $49.9M | ||
| Q4 24 | $376.7M | $66.8M | ||
| Q3 24 | $523.1M | $66.9M | ||
| Q2 24 | $636.7M | $65.2M | ||
| Q1 24 | $581.9M | $75.0M |
| Q4 25 | $734.0M | $15.0M | ||
| Q3 25 | $732.9M | $15.0M | ||
| Q2 25 | $731.8M | $15.0M | ||
| Q1 25 | $730.7M | $15.0M | ||
| Q4 24 | $729.6M | $15.0M | ||
| Q3 24 | $750.5M | — | ||
| Q2 24 | $801.3M | — | ||
| Q1 24 | $800.1M | — |
| Q4 25 | $1.6B | $53.6M | ||
| Q3 25 | $1.5B | $43.7M | ||
| Q2 25 | $1.5B | $295.0K | ||
| Q1 25 | $1.4B | $16.9M | ||
| Q4 24 | $1.4B | $33.0M | ||
| Q3 24 | $1.3B | $46.2M | ||
| Q2 24 | $1.3B | $44.1M | ||
| Q1 24 | $1.2B | $57.2M |
| Q4 25 | $2.7B | $114.9M | ||
| Q3 25 | $2.6B | $104.8M | ||
| Q2 25 | $2.6B | $42.8M | ||
| Q1 25 | $2.5B | $59.1M | ||
| Q4 24 | $2.4B | $76.2M | ||
| Q3 24 | $2.4B | $75.3M | ||
| Q2 24 | $2.4B | $72.4M | ||
| Q1 24 | $2.3B | $82.6M |
| Q4 25 | 0.46× | 0.28× | ||
| Q3 25 | 0.48× | 0.34× | ||
| Q2 25 | 0.49× | 50.85× | ||
| Q1 25 | 0.51× | 0.89× | ||
| Q4 24 | 0.53× | 0.46× | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.5M | $-2.3M |
| 自由现金流经营现金流 - 资本支出 | $74.0M | $-2.3M |
| 自由现金流率自由现金流/营收 | 18.8% | -7.4% |
| 资本支出强度资本支出/营收 | 6.2% | 0.1% |
| 现金转化率经营现金流/净利润 | 2.59× | -0.36× |
| 过去12个月自由现金流最近4个季度 | $215.7M | $-49.5M |
8季度趋势，按日历期对齐
| Q4 25 | $98.5M | $-2.3M | ||
| Q3 25 | $75.0M | $-14.6M | ||
| Q2 25 | $83.3M | $-15.5M | ||
| Q1 25 | $40.6M | $-16.6M | ||
| Q4 24 | $68.7M | $-13.5M | ||
| Q3 24 | $47.3M | $-13.7M | ||
| Q2 24 | $68.5M | $-10.2M | ||
| Q1 24 | $36.2M | $-13.1M |
| Q4 25 | $74.0M | $-2.3M | ||
| Q3 25 | $52.5M | $-14.9M | ||
| Q2 25 | $69.6M | $-15.6M | ||
| Q1 25 | $19.5M | $-16.7M | ||
| Q4 24 | $65.3M | $-13.6M | ||
| Q3 24 | $38.0M | $-13.8M | ||
| Q2 24 | $57.9M | $-10.3M | ||
| Q1 24 | $24.5M | $-13.1M |
| Q4 25 | 18.8% | -7.4% | ||
| Q3 25 | 13.7% | -1725.9% | ||
| Q2 25 | 18.2% | -1861.4% | ||
| Q1 25 | 5.5% | -1927.2% | ||
| Q4 24 | 18.4% | -5392.9% | ||
| Q3 24 | 11.2% | -1394.9% | ||
| Q2 24 | 17.1% | -1325.6% | ||
| Q1 24 | 7.6% | -2116.5% |
| Q4 25 | 6.2% | 0.1% | ||
| Q3 25 | 5.8% | 36.0% | ||
| Q2 25 | 3.6% | 4.1% | ||
| Q1 25 | 5.9% | 12.9% | ||
| Q4 24 | 1.0% | 41.9% | ||
| Q3 24 | 2.8% | 6.9% | ||
| Q2 24 | 3.1% | 13.8% | ||
| Q1 24 | 3.6% | 1.3% |
| Q4 25 | 2.59× | -0.36× | ||
| Q3 25 | 2.70× | — | ||
| Q2 25 | 2.56× | — | ||
| Q1 25 | 1.35× | — | ||
| Q4 24 | 2.46× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.92× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
OBIO
暂无分部数据
